Tolvaptan

Tolvaptan
Product Description

Used to treat adults with autosomal dominant polycystic kidney disease.7.5mg, 15mg, 30mg: is indicated in adults for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH).
15+45mg, 30+60mg, 30+90mg: is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD).
Coripharma`s generic version of Tolvaptan is being developed in our R&D facility located in Iceland, which is run solely on sustainable energy.
Coripharma will finalize the dossier in Q4 2022 and start submitting for our clients within the coming months.

Coripharma

  • IS
  • 2020
    On CPHI since
  • 100 - 249
    Employees
Company types
Pharmaceutical company
Specifications
  • Selling Points
    Quality Service; Sustainability

Coripharma

  • IS
  • 2020
    On CPHI since
  • 100 - 249
    Employees
Company types
Pharmaceutical company

More Products from Coripharma (3)

  • Coripharma Dossier List

    Product Coripharma Dossier List

    We offer out-licensing of our own developed dossiers, along with a range of services that enable our customers to take products to their respective markets at the date of patent expiry and under their own brand. Currently we have over 20 own developed dossiers on our pipeline and our dossier list is readil...
  • Raltegravir 600mg

    Product Raltegravir 600mg

    Raltegravir is an HIV medicine that is used in combination with other HIV medicines to treat patients who are infected with human immunodeficiency virus (HIV‑1), a virus that causes acquired immune deficiency syndrome (AIDS).Raltegravir 600mg Film-coated tablets has passed its pivotal bioequivalence s...
  • Bosutinib

    Product Bosutinib

    Bosutinib is used to treat chronic myeloid leukaemia (CML), a cancer of the white blood cells, in adults with a special chromosome in their cells called the Philadelphia chromosome.Bosutinib is available in three strengths, 100, 400 and 500mg, all three strengths are being developed here in our R&...